Comparison of the efficacy of tacrolimus 0.1% ointment vs calcipotriol/betamethasone in combination with NBUVB in treatment of vitiligo

References

• Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020;236(6):1–6. doi: 10.1159/000506103.
   Web of Science ®Google Scholar
• Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–1212. doi: 10.1111/j.1365-4632.2011.05377.x.
   PubMed Web of Science ®Google Scholar
• Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831–1844. doi: 10.1111/jdv.18257.
   PubMed Web of Science ®Google Scholar
• Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33(3):e13418.
   PubMed Web of Science ®Google Scholar
• Ezzedine K, Lim H, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the vitiligo global issues consensus conference. Pigment Cell Melanoma Res. 2013;25:1–28.
   Web of Science ®Google Scholar
• Whitton M, Pinart M, Batchelor JM, et al. Evidence-based management of vitiligo: summary of a cochrane systematic review. Br J Dermatol. 2016;174(5):962–969. doi: 10.1111/bjd.14356.
   PubMed Web of Science ®Google Scholar
• Nordal EJ, Guleng GE, Rönnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25(12):1440–1443. doi: 10.1111/j.1468-3083.2011.04002.x.
   PubMed Web of Science ®Google Scholar
• Akdeniz N, Yavuz IH, Gunes Bilgili S, et al. Comparison of efficacy of narrow band UVB therapies with UVB alone, in combination with calcipotriol, and with betamethasoneand calcipotriol in vitiligo. J Dermatolog Treat. 2014;25(3):196–199. doi: 10.3109/09546634.2013.777381.
   PubMed Web of Science ®Google Scholar
• Ibrahim ZA, Hassan GF, Elgendy HY, et al. Evaluation of the efficacy of transdermal drug delivery of calcipotriol plus betamethasone versus tacrolimus in the treatment of vitiligo. J Cosmet Dermatol. 2019;18(2):581–588. doi: 10.1111/jocd.12704.
   PubMed Web of Science ®Google Scholar
• Sisti A, Sisti G, Oranges CM. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. Ann Bras Dermatol. 2016;91(2):187–195. doi: 10.1590/abd1806-4841.20164012.
   PubMed Web of Science ®Google Scholar
• AlGhamdi K, Kumar A, Moussa N. The role of vitamin D in melanogenesis with an emphasis on vitiligo. Indian J Dermatol Venereol Leprol. 2013;79(6):750–758. doi: 10.4103/0378-6323.120720.
   PubMed Web of Science ®Google Scholar
• Alshiyab DM, Al-Qarqaz FA, Heis LH, et al. Assessment of serum vitamin D levels in patients with vitiligo in Jordan: a case-control study. Dermatol Res Pract. 2019;2019:2048409–2048404. doi: 10.1155/2019/2048409.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Dogra S, Parsad D, et al. Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. Int J Dermatol. 2005;44(1):57–60. doi: 10.1111/j.1365-4632.2004.02329.x.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol. 2002;47(5):789–791. doi: 10.1067/mjd.2002.126250.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol. 2004;51(1):52–61. doi: 10.1016/j.jaad.2003.12.031.
   PubMed Web of Science ®Google Scholar
• Seneschal J, Duplaine A, Maillard H, et al. Efficacy and safety of tacrolimus 0.1% for the treatment of facial vitiligo: a multicenter randomized, double-blinded, vehicle-controlled study. J Invest Dermatol. 2021;141(7):1728–1734. doi: 10.1016/j.jid.2020.12.028.
   PubMed Web of Science ®Google Scholar
• Saleh R, Ahmed AAE, M Abd-Elmagid W. Efficacy of topical tacrolimus 0.03% monotherapy in the treatment of non-segmental vitiligo: a randomized, controlled trial. J Cosmet Dermatol. 2021;20(12):3943–3952. doi: 10.1111/jocd.14041.
   PubMed Web of Science ®Google Scholar
• Zhu B, Liu C, Zhang L, et al. Comparison of NB-UVB combination therapy regimens for vitiligo: a systematic review and network meta-analysis. J Cosmet Dermatol. 2023;22(3):1083–1098. doi: 10.1111/jocd.15534.
   PubMed Web of Science ®Google Scholar
• Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20(3):269–273. doi: 10.1111/j.1468-3083.2006.01420.x.
   PubMed Web of Science ®Google Scholar
• Aliyev R, Finsterer J. Systemic toxicity to betamethasone ointment. Clin Case Rep. 2020;8(9):1635–1637. doi: 10.1002/ccr3.2957.
   PubMed Web of Science ®Google Scholar
• Hartmann A, Bröcker EB, Hamm H. Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-month prospective study. Acta Derm Venereol. 2008;88(5):474–479. doi: 10.2340/00015555-0464.
   PubMed Web of Science ®Google Scholar